Mr. J.J. Wilson reports

OPTIMI ANNOUNCES PUBLIC FILING OF REGISTRATION STATEMENT FOR PROPOSED U.S. INITIAL PUBLIC OFFERING

Optimi Health Corp. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common shares in the United States.

The number of common shares to be sold and the price range for the proposed offering have not yet been determined. The company has filed an application to list its common shares on the Nasdaq Capital Market under the symbol OPTH. The filing of the application does not guarantee the listing of the company's common shares, and the company may withdraw its application due to future circumstances, market conditions or other factors.

Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunning manager for the proposed offering.

The offering will be made only by means of a prospectus forming a part of the registration statement. Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners LLC, 4 World Trade Center (29th floor), New York, N.Y., 1000, by phone at 929-833-1246 or by e-mail to prospectus@titanpartnersgrp.com.

A registration statement on Form F-1 (file No. 333-290086) relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

About Optimi Health Corp.

Optimi Health is a Health Canada-licensed, GMP-compliant (good manufacturing practice) manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the company aims to support the global advancement of mental health therapies through rigorous compliance, innovation and collaboration.

We seek Safe Harbor.